June Industries has reported a net loss of ₹0.46 crore for FY2025-26, a significant increase from the previous year, as it transitions from IT services to pharmaceutical and hygiene product trading. June Enterprises Private Limited now holds a majority stake.
June Industries Posts ₹0.46 Crore Net Loss as Business Model Shifts
June Industries Ltd has reported a net loss of ₹0.4606 crore (₹46.06 lakh) for the financial year 2025-26, a substantial widening from a negligible loss in the prior year. This comes as the company undergoes a strategic transformation, exiting IT services to focus on trading pharmaceutical, hygiene, and cleanroom products.
Reader Takeaway: Widening losses pressure profitability despite a new asset-light business model.
What just happened
June Industries Ltd, formerly Kashyap Tele-Medicines Limited, has widened its net loss to ₹0.46 crore in FY2025-26. Revenue from operations remained stagnant at ₹0.197 crore. The company also paid fines to BSE for non-compliance and saw significant board changes.
Why this matters
The widening losses signal significant costs associated with the business transition, including higher employee benefits and administrative expenses. The strategic pivot to an asset-light model in pharmaceutical and hygiene trading is in its early stages, and execution risk remains.
The backstory
June Industries Ltd has completed a name change and a strategic exit from its previous IT and software services business. It is now focused on the trading of pharmaceutical, hygiene, and cleanroom products. June Enterprises Private Limited has acquired a 60.88% stake, making it a subsidiary.
What changes now
The company is operating under a new business model focused on trading. An asset-light approach is being adopted to manage capital expenditure. The new majority owner, June Enterprises Private Limited, will likely steer the company's future strategy.
Risks to watch
Key risks include the execution of the new business pivot, managing increased operational costs leading to widening losses, and ensuring regulatory compliance after past lapses. Board stability is also a concern given recent turnover.
Peer comparison
Companies in the pharmaceutical trading sector typically focus on distribution networks and product sourcing. June Industries' transition to this sector, while aiming for an asset-light model, needs to demonstrate competitive efficiency against established players.
Context metrics (time-bound)
For FY2025-26, June Industries reported revenue from operations of ₹0.197 crore and a net loss of ₹0.4606 crore. This compares to FY2024-25 figures of ₹0.192 crore revenue and a net loss of ₹0.0003 crore.
What to track next
Investors should monitor the company's ability to improve revenue, control administrative costs, and achieve profitability under the new business focus. Board and management stability will also be crucial indicators.